Like pls_老虎社区_美港股上老虎

2021-09-25

Like pls

IPO opening reminder: Cue Health opens for trading at $19.2, up 20% from IPO price.

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":861596413,"tweetId":"861596413","gmtCreate":1632518548932,"gmtModify":1632714315301,"author":{"id":3570342809089528,"idStr":"3570342809089528","authorId":3570342809089528,"authorIdStr":"3570342809089528","name":"phantom74","avatar":"https://static.tigerbbs.com/c87ef2af41b8696be86cceafb5b5723d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":56,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Like pls</body></html>","htmlText":"<html><head></head><body>Like pls</body></html>","text":"Like pls","highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":4,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/861596413","repostId":1104085778,"repostType":4,"repost":{"id":"1104085778","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632498166,"share":"https://www.laohu8.com/m/news/1104085778?lang=&edition=full","pubTime":"2021-09-24 23:42","market":"us","language":"en","title":"IPO opening reminder: Cue Health opens for trading at $19.2, up 20% from IPO price.","url":"https://stock-news.laohu8.com/highlight/detail?id=1104085778","media":"Tiger Newspress","summary":"(Sept 24) Cue Health Inc. opens for trading at $19.2, up 20% from IPO price.\n\nCompany & Technology\nS","content":"(Sept 24)&nbsp;<a href=\"https://laohu8.com/S/HLTH\">Cue Health Inc.</a> opens for trading at $19.2, up 20% from IPO price.\n<img src=\"https://static.tigerbbs.com/c7270662a08ec3dac176aa52bf5cbd1a\" tg-width=\"902\" tg-height=\"560\" referrerpolicy=\"no-referrer\">\nCompany &amp; Technology\nSan Diego, California-based Cue was founded to first develop a COVID-19 test kit and integrated information platform for processing and communication.\nManagement is headed by co-founder, Chairman and CEO Ayub Khattak, who has been with the firm since inception and holds a B.S. in mathematics from UCLA.\nThe company’s primary offerings in its Cue Integrated Care Platform:\n<ul>\n <li>Health monitoring system</li>\n <li>Rader</li>\n <li>Cartridge</li>\n <li>Wand</li>\n <li>Data</li>\n <li>Delivery apps</li>\n <li>Enterprise dashboard</li>\n <li>Ecosystem integrations</li>\n</ul>\nCue has received at least $176 million in equity investment from investors including ACME Capital, Cove Investors, Decheng Capital China Life Sciences, Madrone and NVGA I.\nCustomer/User Acquisition\nThe company pursues healthcare provider relationships through its in-house direct sales team focused on healthcare providers, large enterprises and public sector clients.\nManagement expects 2021 customer demand for its COVID-19 test kits to exceed its manufacturing capacity.\nSales and Marketing expenses as a percentage of total revenue have varied as revenues have increased sharply, as the figures below indicate:\n<table>\n <tbody>\n <tr>\n <td>Sales and Marketing</td>\n <td>Expenses vs. Revenue</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Percentage</td>\n </tr>\n <tr>\n <td>Six Mos. Ended June 30, 2021</td>\n <td>1.0%</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>3.1%</td>\n </tr>\n <tr>\n <td>2019</td>\n <td>1.3%</td>\n </tr>\n </tbody>\n</table>\nThe Sales and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Sales and Marketing spend, was 100.5x in the most recent reporting period, as shown in the table below:\n<table>\n <tbody>\n <tr>\n <td>Sales and Marketing</td>\n <td>Efficiency Rate</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Multiple</td>\n </tr>\n <tr>\n <td>Six Mos. Ended June 30, 2021</td>\n <td>100.5</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>22.9</td>\n </tr>\n </tbody>\n</table>\nMarket &amp; Competition\nAccording to a 2020 marketresearch reportby Grand View Research, the global market for COVID-19 detection kits was an estimated $3.28 billion in 2020 and is expected to reach $5 billion by 2027.\nThis represents a forecast CAGR of 5.05% from 2021 to 2027.\nThe main drivers for this expected growth are a strong growth in demand for testing services of all types on a global basis.\nAlso, below is a chart showing the market share of use of detection kits by end-user type:\n<img src=\"https://static.tigerbbs.com/4b7fc60b336bae7685e08132f8176b57\" tg-width=\"1158\" tg-height=\"618\" referrerpolicy=\"no-referrer\">\n(Source)\nMajor competitive or other industry participants include:\n<ul>\n <li>Abbott Laboratories(NYSE:ABT)</li>\n <li>Becton, Dickinson(NYSE:BDX)</li>\n <li>bioMerieux(OTCPK:BMXMF)</li>\n <li>Bio-Rad Laboratories(NYSE:BIO)</li>\n <li>Danaher(NYSE:DHR)</li>\n <li>Ellume Limited</li>\n <li>Everly Health</li>\n <li>Roche(OTCQX:RHHBY)(OTCQX:RHHBF)</li>\n <li>Fluidigm(NASDAQ:FLDM)</li>\n <li>GenMark Diagnostics(NASDAQ:GNMK)</li>\n <li>Others</li>\n</ul>\nFinancial Performance\nCue’s recent financial results can be summarized as follows:\n<ul>\n <li>Sharply growing top line revenue</li>\n <li>Increasing gross profit and variable gross margin</li>\n <li>A swing to operating profit and net income</li>\n <li>Variable cash flow from operations</li>\n</ul>\nBelow are relevant financial results derived from the firm’s registration statement:\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td>Total Revenue</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Total Revenue</td>\n <td>% Variance vs. Prior</td>\n </tr>\n <tr>\n <td>Six Mos. Ended June 30, 2021</td>\n <td>$ 201,922,000</td>\n <td>3971.0%</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>$ 22,953,000</td>\n <td>246.4%</td>\n </tr>\n <tr>\n <td>2019</td>\n <td>$ 6,626,000</td>\n </tr>\n <tr></tr>\n <tr>\n <td>Gross Profit (Loss)</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Gross Profit (Loss)</td>\n <td>% Variance vs. Prior</td>\n </tr>\n <tr>\n <td>Six Mos. Ended June 30, 2021</td>\n <td>$ 116,745,000</td>\n <td>2253.7%</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>$ 8,002,000</td>\n <td>20.8%</td>\n </tr>\n <tr>\n <td>2019</td>\n <td>$ 6,626,000</td>\n </tr>\n <tr></tr>\n <tr>\n <td>Gross Margin</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Gross Margin</td>\n </tr>\n <tr>\n <td>Six Mos. Ended June 30, 2021</td>\n <td>57.82%</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>34.86%</td>\n </tr>\n <tr>\n <td>2019</td>\n <td>100.00%</td>\n </tr>\n <tr></tr>\n <tr>\n <td>Operating Profit (Loss)</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Operating Profit (Loss)</td>\n <td>Operating Margin</td>\n </tr>\n <tr>\n <td>Six Mos. Ended June 30, 2021</td>\n <td>$ 79,463,000</td>\n <td>39.4%</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>$ (45,126,000)</td>\n <td>-196.6%</td>\n </tr>\n <tr>\n <td>2019</td>\n <td>$ (20,767,000)</td>\n <td>-313.4%</td>\n </tr>\n <tr></tr>\n <tr>\n <td>Net Income (Loss)</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Net Income (Loss)</td>\n </tr>\n <tr>\n <td>Six Mos. Ended June 30, 2021</td>\n <td>$ 32,840,000</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>$ (47,352,000)</td>\n </tr>\n <tr>\n <td>2019</td>\n <td>$ (20,606,000)</td>\n </tr>\n <tr></tr>\n <tr>\n <td>Cash Flow From Operations</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Cash Flow From Operations</td>\n </tr>\n <tr>\n <td>Six Mos. Ended June 30, 2021</td>\n <td>$ (37,812,000)</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>$ 92,655,000</td>\n </tr>\n <tr>\n <td>2019</td>\n <td>$ (12,996,000)</td>\n </tr>\n </tbody>\n</table>\nAs of June 30, 2021, Cue had $246.3 million in cash and $516.3 million in total liabilities.\nFree cash flow during the twelve months ended June 30, 2021, was negative ($60 million).\nValuation Metrics\nBelow is a table of relevant capitalization and valuation figures for the company:\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td>Measure [TTM]</td>\n <td>Amount</td>\n </tr>\n <tr>\n <td>Market Capitalization at IPO</td>\n <td>$2,299,981,232</td>\n </tr>\n <tr>\n <td>Enterprise Value</td>\n <td>$1,874,455,232</td>\n </tr>\n <tr>\n <td>Price / Sales</td>\n <td>10.46</td>\n </tr>\n <tr>\n <td>EV / Revenue</td>\n <td>8.52</td>\n </tr>\n <tr>\n <td>EV / EBITDA</td>\n <td>35.46</td>\n </tr>\n <tr>\n <td>Earnings Per Share</td>\n <td>$0.03</td>\n </tr>\n <tr>\n <td>Float To Outstanding Shares Ratio</td>\n <td>8.70%</td>\n </tr>\n <tr>\n <td>Proposed IPO Midpoint Price per Share</td>\n <td>$16.00</td>\n </tr>\n <tr>\n <td>Net Free Cash Flow</td>\n <td>-$59,920,000</td>\n </tr>\n <tr>\n <td>Free Cash Flow Yield Per Share</td>\n <td>-2.61%</td>\n </tr>\n <tr>\n <td>Revenue Growth Rate</td>\n <td>3971.01%</td>\n </tr>\n </tbody>\n</table>\nAs a reference, a potential partial and imperfect public comparable to Cue would be Bio-Rad (BIO); below is a comparison of their primary valuation metrics:\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td>Metric</td>\n <td>Bio-Rad (BIO)</td>\n <td>Cue Health (HLTH)</td>\n <td>Variance</td>\n </tr>\n <tr>\n <td>Price / Sales</td>\n <td>8.15</td>\n <td>10.46</td>\n <td>28.3%</td>\n </tr>\n <tr>\n <td>EV / Revenue</td>\n <td>7.82</td>\n <td>8.52</td>\n <td>9.0%</td>\n </tr>\n <tr>\n <td>EV / EBITDA</td>\n <td>31.66</td>\n <td>35.46</td>\n <td>12.0%</td>\n </tr>\n <tr>\n <td>Earnings Per Share</td>\n <td>$134.05</td>\n <td>$0.03</td>\n <td>-100.0%</td>\n </tr>\n <tr>\n <td>Revenue Growth Rate</td>\n <td>25.6%</td>\n <td>3971.01%</td>\n <td>15436.03%</td>\n </tr>\n <tr>\n <td>(Glossary Of Terms)</td>\n </tr>\n </tbody>\n</table>\nCommentary\nCue is seeking public investment capital to further scale its commercialization operations as well as continue its R &amp; D efforts.\nThe company’s financials show sharply growing top line revenue, strong growth in gross profit and variable gross margin, a swing to operating profit and net income and highly fluctuating cash flow from or use in operations\nFree cash flow for the twelve months ended June 30, 2021, was an eye-popping negative ($60 million).\nSales and Marketing expenses as a percentage of total revenue have fluctuated as revenues have increased dramatically; its Sales and Marketing efficiency rate was an extremely high 100.5x in the most recent reporting period.\nThe market opportunity for COVID-19 and related test kit platforms is large and will likely grow at a high rate of growth over the coming years as countries around the world seek to bolster their testing capabilities in the wake of the recent global pandemic.\nGoldman Sachs is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 39.9% since their IPO. This is a mid-tier performance for all major underwriters during the period.\nThe primary risk to the firm now is that it is essentially a one-product company, so its revenue base is heavily concentrated.\nAs for valuation, compared to partial competitor Bio-Rad Laboratories, the IPO is reasonably valued on a revenue multiple, although Cue is growing at a much higher rate of growth from a much lower revenue base, so the comparison is strained at best.\nGiven Cue’s growth trajectory, profitability and reasonable IPO valuation, the IPO is worth consideration.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO opening reminder: Cue Health opens for trading at $19.2, up 20% from IPO price.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO opening reminder: Cue Health opens for trading at $19.2, up 20% from IPO price.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nTiger Newspress \n2021-09-24 23:42\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n(Sept 24)&nbsp;<a href=\"https://laohu8.com/S/HLTH\">Cue Health Inc.</a> opens for trading at $19.2, up 20% from IPO price.\n<img src=\"https://static.tigerbbs.com/c7270662a08ec3dac176aa52bf5cbd1a\" tg-width=\"902\" tg-height=\"560\" referrerpolicy=\"no-referrer\">\nCompany &amp; Technology\nSan Diego, California-based Cue was founded to first develop a COVID-19 test kit and integrated information platform for processing and communication.\nManagement is headed by co-founder, Chairman and CEO Ayub Khattak, who has been with the firm since inception and holds a B.S. in mathematics from UCLA.\nThe company’s primary offerings in its Cue Integrated Care Platform:\n<ul>\n <li>Health monitoring system</li>\n <li>Rader</li>\n <li>Cartridge</li>\n <li>Wand</li>\n <li>Data</li>\n <li>Delivery apps</li>\n <li>Enterprise dashboard</li>\n <li>Ecosystem integrations</li>\n</ul>\nCue has received at least $176 million in equity investment from investors including ACME Capital, Cove Investors, Decheng Capital China Life Sciences, Madrone and NVGA I.\nCustomer/User Acquisition\nThe company pursues healthcare provider relationships through its in-house direct sales team focused on healthcare providers, large enterprises and public sector clients.\nManagement expects 2021 customer demand for its COVID-19 test kits to exceed its manufacturing capacity.\nSales and Marketing expenses as a percentage of total revenue have varied as revenues have increased sharply, as the figures below indicate:\n<table>\n <tbody>\n <tr>\n <td>Sales and Marketing</td>\n <td>Expenses vs. Revenue</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Percentage</td>\n </tr>\n <tr>\n <td>Six Mos. Ended June 30, 2021</td>\n <td>1.0%</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>3.1%</td>\n </tr>\n <tr>\n <td>2019</td>\n <td>1.3%</td>\n </tr>\n </tbody>\n</table>\nThe Sales and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Sales and Marketing spend, was 100.5x in the most recent reporting period, as shown in the table below:\n<table>\n <tbody>\n <tr>\n <td>Sales and Marketing</td>\n <td>Efficiency Rate</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Multiple</td>\n </tr>\n <tr>\n <td>Six Mos. Ended June 30, 2021</td>\n <td>100.5</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>22.9</td>\n </tr>\n </tbody>\n</table>\nMarket &amp; Competition\nAccording to a 2020 marketresearch reportby Grand View Research, the global market for COVID-19 detection kits was an estimated $3.28 billion in 2020 and is expected to reach $5 billion by 2027.\nThis represents a forecast CAGR of 5.05% from 2021 to 2027.\nThe main drivers for this expected growth are a strong growth in demand for testing services of all types on a global basis.\nAlso, below is a chart showing the market share of use of detection kits by end-user type:\n<img src=\"https://static.tigerbbs.com/4b7fc60b336bae7685e08132f8176b57\" tg-width=\"1158\" tg-height=\"618\" referrerpolicy=\"no-referrer\">\n(Source)\nMajor competitive or other industry participants include:\n<ul>\n <li>Abbott Laboratories(NYSE:ABT)</li>\n <li>Becton, Dickinson(NYSE:BDX)</li>\n <li>bioMerieux(OTCPK:BMXMF)</li>\n <li>Bio-Rad Laboratories(NYSE:BIO)</li>\n <li>Danaher(NYSE:DHR)</li>\n <li>Ellume Limited</li>\n <li>Everly Health</li>\n <li>Roche(OTCQX:RHHBY)(OTCQX:RHHBF)</li>\n <li>Fluidigm(NASDAQ:FLDM)</li>\n <li>GenMark Diagnostics(NASDAQ:GNMK)</li>\n <li>Others</li>\n</ul>\nFinancial Performance\nCue’s recent financial results can be summarized as follows:\n<ul>\n <li>Sharply growing top line revenue</li>\n <li>Increasing gross profit and variable gross margin</li>\n <li>A swing to operating profit and net income</li>\n <li>Variable cash flow from operations</li>\n</ul>\nBelow are relevant financial results derived from the firm’s registration statement:\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td>Total Revenue</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Total Revenue</td>\n <td>% Variance vs. Prior</td>\n </tr>\n <tr>\n <td>Six Mos. Ended June 30, 2021</td>\n <td>$ 201,922,000</td>\n <td>3971.0%</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>$ 22,953,000</td>\n <td>246.4%</td>\n </tr>\n <tr>\n <td>2019</td>\n <td>$ 6,626,000</td>\n </tr>\n <tr></tr>\n <tr>\n <td>Gross Profit (Loss)</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Gross Profit (Loss)</td>\n <td>% Variance vs. Prior</td>\n </tr>\n <tr>\n <td>Six Mos. Ended June 30, 2021</td>\n <td>$ 116,745,000</td>\n <td>2253.7%</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>$ 8,002,000</td>\n <td>20.8%</td>\n </tr>\n <tr>\n <td>2019</td>\n <td>$ 6,626,000</td>\n </tr>\n <tr></tr>\n <tr>\n <td>Gross Margin</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Gross Margin</td>\n </tr>\n <tr>\n <td>Six Mos. Ended June 30, 2021</td>\n <td>57.82%</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>34.86%</td>\n </tr>\n <tr>\n <td>2019</td>\n <td>100.00%</td>\n </tr>\n <tr></tr>\n <tr>\n <td>Operating Profit (Loss)</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Operating Profit (Loss)</td>\n <td>Operating Margin</td>\n </tr>\n <tr>\n <td>Six Mos. Ended June 30, 2021</td>\n <td>$ 79,463,000</td>\n <td>39.4%</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>$ (45,126,000)</td>\n <td>-196.6%</td>\n </tr>\n <tr>\n <td>2019</td>\n <td>$ (20,767,000)</td>\n <td>-313.4%</td>\n </tr>\n <tr></tr>\n <tr>\n <td>Net Income (Loss)</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Net Income (Loss)</td>\n </tr>\n <tr>\n <td>Six Mos. Ended June 30, 2021</td>\n <td>$ 32,840,000</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>$ (47,352,000)</td>\n </tr>\n <tr>\n <td>2019</td>\n <td>$ (20,606,000)</td>\n </tr>\n <tr></tr>\n <tr>\n <td>Cash Flow From Operations</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Cash Flow From Operations</td>\n </tr>\n <tr>\n <td>Six Mos. Ended June 30, 2021</td>\n <td>$ (37,812,000)</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>$ 92,655,000</td>\n </tr>\n <tr>\n <td>2019</td>\n <td>$ (12,996,000)</td>\n </tr>\n </tbody>\n</table>\nAs of June 30, 2021, Cue had $246.3 million in cash and $516.3 million in total liabilities.\nFree cash flow during the twelve months ended June 30, 2021, was negative ($60 million).\nValuation Metrics\nBelow is a table of relevant capitalization and valuation figures for the company:\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td>Measure [TTM]</td>\n <td>Amount</td>\n </tr>\n <tr>\n <td>Market Capitalization at IPO</td>\n <td>$2,299,981,232</td>\n </tr>\n <tr>\n <td>Enterprise Value</td>\n <td>$1,874,455,232</td>\n </tr>\n <tr>\n <td>Price / Sales</td>\n <td>10.46</td>\n </tr>\n <tr>\n <td>EV / Revenue</td>\n <td>8.52</td>\n </tr>\n <tr>\n <td>EV / EBITDA</td>\n <td>35.46</td>\n </tr>\n <tr>\n <td>Earnings Per Share</td>\n <td>$0.03</td>\n </tr>\n <tr>\n <td>Float To Outstanding Shares Ratio</td>\n <td>8.70%</td>\n </tr>\n <tr>\n <td>Proposed IPO Midpoint Price per Share</td>\n <td>$16.00</td>\n </tr>\n <tr>\n <td>Net Free Cash Flow</td>\n <td>-$59,920,000</td>\n </tr>\n <tr>\n <td>Free Cash Flow Yield Per Share</td>\n <td>-2.61%</td>\n </tr>\n <tr>\n <td>Revenue Growth Rate</td>\n <td>3971.01%</td>\n </tr>\n </tbody>\n</table>\nAs a reference, a potential partial and imperfect public comparable to Cue would be Bio-Rad (BIO); below is a comparison of their primary valuation metrics:\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td>Metric</td>\n <td>Bio-Rad (BIO)</td>\n <td>Cue Health (HLTH)</td>\n <td>Variance</td>\n </tr>\n <tr>\n <td>Price / Sales</td>\n <td>8.15</td>\n <td>10.46</td>\n <td>28.3%</td>\n </tr>\n <tr>\n <td>EV / Revenue</td>\n <td>7.82</td>\n <td>8.52</td>\n <td>9.0%</td>\n </tr>\n <tr>\n <td>EV / EBITDA</td>\n <td>31.66</td>\n <td>35.46</td>\n <td>12.0%</td>\n </tr>\n <tr>\n <td>Earnings Per Share</td>\n <td>$134.05</td>\n <td>$0.03</td>\n <td>-100.0%</td>\n </tr>\n <tr>\n <td>Revenue Growth Rate</td>\n <td>25.6%</td>\n <td>3971.01%</td>\n <td>15436.03%</td>\n </tr>\n <tr>\n <td>(Glossary Of Terms)</td>\n </tr>\n </tbody>\n</table>\nCommentary\nCue is seeking public investment capital to further scale its commercialization operations as well as continue its R &amp; D efforts.\nThe company’s financials show sharply growing top line revenue, strong growth in gross profit and variable gross margin, a swing to operating profit and net income and highly fluctuating cash flow from or use in operations\nFree cash flow for the twelve months ended June 30, 2021, was an eye-popping negative ($60 million).\nSales and Marketing expenses as a percentage of total revenue have fluctuated as revenues have increased dramatically; its Sales and Marketing efficiency rate was an extremely high 100.5x in the most recent reporting period.\nThe market opportunity for COVID-19 and related test kit platforms is large and will likely grow at a high rate of growth over the coming years as countries around the world seek to bolster their testing capabilities in the wake of the recent global pandemic.\nGoldman Sachs is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 39.9% since their IPO. This is a mid-tier performance for all major underwriters during the period.\nThe primary risk to the firm now is that it is essentially a one-product company, so its revenue base is heavily concentrated.\nAs for valuation, compared to partial competitor Bio-Rad Laboratories, the IPO is reasonably valued on a revenue multiple, although Cue is growing at a much higher rate of growth from a much lower revenue base, so the comparison is strained at best.\nGiven Cue’s growth trajectory, profitability and reasonable IPO valuation, the IPO is worth consideration.\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HLTH":"Cue Health Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104085778","content_text":"(Sept 24) Cue Health Inc. opens for trading at $19.2, up 20% from IPO price.\n\nCompany & Technology\nSan Diego, California-based Cue was founded to first develop a COVID-19 test kit and integrated information platform for processing and communication.\nManagement is headed by co-founder, Chairman and CEO Ayub Khattak, who has been with the firm since inception and holds a B.S. in mathematics from UCLA.\nThe company’s primary offerings in its Cue Integrated Care Platform:\n\nHealth monitoring system\nRader\nCartridge\nWand\nData\nDelivery apps\nEnterprise dashboard\nEcosystem integrations\n\nCue has received at least $176 million in equity investment from investors including ACME Capital, Cove Investors, Decheng Capital China Life Sciences, Madrone and NVGA I.\nCustomer/User Acquisition\nThe company pursues healthcare provider relationships through its in-house direct sales team focused on healthcare providers, large enterprises and public sector clients.\nManagement expects 2021 customer demand for its COVID-19 test kits to exceed its manufacturing capacity.\nSales and Marketing expenses as a percentage of total revenue have varied as revenues have increased sharply, as the figures below indicate:\n\n\n\nSales and Marketing\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nSix Mos. Ended June 30, 2021\n1.0%\n\n\n2020\n3.1%\n\n\n2019\n1.3%\n\n\n\nThe Sales and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Sales and Marketing spend, was 100.5x in the most recent reporting period, as shown in the table below:\n\n\n\nSales and Marketing\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nSix Mos. Ended June 30, 2021\n100.5\n\n\n2020\n22.9\n\n\n\nMarket & Competition\nAccording to a 2020 marketresearch reportby Grand View Research, the global market for COVID-19 detection kits was an estimated $3.28 billion in 2020 and is expected to reach $5 billion by 2027.\nThis represents a forecast CAGR of 5.05% from 2021 to 2027.\nThe main drivers for this expected growth are a strong growth in demand for testing services of all types on a global basis.\nAlso, below is a chart showing the market share of use of detection kits by end-user type:\n\n(Source)\nMajor competitive or other industry participants include:\n\nAbbott Laboratories(NYSE:ABT)\nBecton, Dickinson(NYSE:BDX)\nbioMerieux(OTCPK:BMXMF)\nBio-Rad Laboratories(NYSE:BIO)\nDanaher(NYSE:DHR)\nEllume Limited\nEverly Health\nRoche(OTCQX:RHHBY)(OTCQX:RHHBF)\nFluidigm(NASDAQ:FLDM)\nGenMark Diagnostics(NASDAQ:GNMK)\nOthers\n\nFinancial Performance\nCue’s recent financial results can be summarized as follows:\n\nSharply growing top line revenue\nIncreasing gross profit and variable gross margin\nA swing to operating profit and net income\nVariable cash flow from operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\n\n\n\nTotal Revenue\n\n\nPeriod\nTotal Revenue\n% Variance vs. Prior\n\n\nSix Mos. Ended June 30, 2021\n$ 201,922,000\n3971.0%\n\n\n2020\n$ 22,953,000\n246.4%\n\n\n2019\n$ 6,626,000\n\n\n\nGross Profit (Loss)\n\n\nPeriod\nGross Profit (Loss)\n% Variance vs. Prior\n\n\nSix Mos. Ended June 30, 2021\n$ 116,745,000\n2253.7%\n\n\n2020\n$ 8,002,000\n20.8%\n\n\n2019\n$ 6,626,000\n\n\n\nGross Margin\n\n\nPeriod\nGross Margin\n\n\nSix Mos. Ended June 30, 2021\n57.82%\n\n\n2020\n34.86%\n\n\n2019\n100.00%\n\n\n\nOperating Profit (Loss)\n\n\nPeriod\nOperating Profit (Loss)\nOperating Margin\n\n\nSix Mos. Ended June 30, 2021\n$ 79,463,000\n39.4%\n\n\n2020\n$ (45,126,000)\n-196.6%\n\n\n2019\n$ (20,767,000)\n-313.4%\n\n\n\nNet Income (Loss)\n\n\nPeriod\nNet Income (Loss)\n\n\nSix Mos. Ended June 30, 2021\n$ 32,840,000\n\n\n2020\n$ (47,352,000)\n\n\n2019\n$ (20,606,000)\n\n\n\nCash Flow From Operations\n\n\nPeriod\nCash Flow From Operations\n\n\nSix Mos. Ended June 30, 2021\n$ (37,812,000)\n\n\n2020\n$ 92,655,000\n\n\n2019\n$ (12,996,000)\n\n\n\nAs of June 30, 2021, Cue had $246.3 million in cash and $516.3 million in total liabilities.\nFree cash flow during the twelve months ended June 30, 2021, was negative ($60 million).\nValuation Metrics\nBelow is a table of relevant capitalization and valuation figures for the company:\n\n\n\n\nMeasure [TTM]\nAmount\n\n\nMarket Capitalization at IPO\n$2,299,981,232\n\n\nEnterprise Value\n$1,874,455,232\n\n\nPrice / Sales\n10.46\n\n\nEV / Revenue\n8.52\n\n\nEV / EBITDA\n35.46\n\n\nEarnings Per Share\n$0.03\n\n\nFloat To Outstanding Shares Ratio\n8.70%\n\n\nProposed IPO Midpoint Price per Share\n$16.00\n\n\nNet Free Cash Flow\n-$59,920,000\n\n\nFree Cash Flow Yield Per Share\n-2.61%\n\n\nRevenue Growth Rate\n3971.01%\n\n\n\nAs a reference, a potential partial and imperfect public comparable to Cue would be Bio-Rad (BIO); below is a comparison of their primary valuation metrics:\n\n\n\n\nMetric\nBio-Rad (BIO)\nCue Health (HLTH)\nVariance\n\n\nPrice / Sales\n8.15\n10.46\n28.3%\n\n\nEV / Revenue\n7.82\n8.52\n9.0%\n\n\nEV / EBITDA\n31.66\n35.46\n12.0%\n\n\nEarnings Per Share\n$134.05\n$0.03\n-100.0%\n\n\nRevenue Growth Rate\n25.6%\n3971.01%\n15436.03%\n\n\n(Glossary Of Terms)\n\n\n\nCommentary\nCue is seeking public investment capital to further scale its commercialization operations as well as continue its R & D efforts.\nThe company’s financials show sharply growing top line revenue, strong growth in gross profit and variable gross margin, a swing to operating profit and net income and highly fluctuating cash flow from or use in operations\nFree cash flow for the twelve months ended June 30, 2021, was an eye-popping negative ($60 million).\nSales and Marketing expenses as a percentage of total revenue have fluctuated as revenues have increased dramatically; its Sales and Marketing efficiency rate was an extremely high 100.5x in the most recent reporting period.\nThe market opportunity for COVID-19 and related test kit platforms is large and will likely grow at a high rate of growth over the coming years as countries around the world seek to bolster their testing capabilities in the wake of the recent global pandemic.\nGoldman Sachs is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 39.9% since their IPO. This is a mid-tier performance for all major underwriters during the period.\nThe primary risk to the firm now is that it is essentially a one-product company, so its revenue base is heavily concentrated.\nAs for valuation, compared to partial competitor Bio-Rad Laboratories, the IPO is reasonably valued on a revenue multiple, although Cue is growing at a much higher rate of growth from a much lower revenue base, so the comparison is strained at best.\nGiven Cue’s growth trajectory, profitability and reasonable IPO valuation, the IPO is worth consideration.","news_type":1},"isVote":1,"tweetType":1,"viewCount":178,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/861596413"}